ICYMI: Op-Ed by Rep. Gus Bilirakis on Lowering Drug Costs

Yesterday, U.S. Representative Gus Bilirakis of Florida published an op-ed outlining how to “Lower Drug Costs Through Competition and Innovation.” Bilirakis writes that “leveraging the power of the free market and incentivizing competition among drug makers will drive costs down – not government mandates.” He cites the success of the Medicare Part D program – holding a 90 percent satisfaction rate among seniors and coming in significantly under budget from original CBO estimates – to show that private sector competition helps patients afford needed medicines.

In the Part D program, plans compete for consumers’ business and aggressively negotiate discounts and rebates from drug manufacturers. A recent study of 12 widely used therapeutic classes in Part D found that plans received average discounts of over 35 percent.Bilirakis closes by noting:

Bilirakis closes by noting:

We can modernize the FDA and clear the backlog of generic drugs waiting for approval. We can reduce unnecessary regulations that hinder innovation and competition. We can remove legal and regulatory barriers so insurers and drug innovators can make more arrangements to “pay for performance.” And we can quickly implement the bipartisan 21st Century Cures Act, using real-world evidence and innovative clinical trial design to get new medicines to market faster.

In the end, we all want affordable prescription drugs and a health care system that spurs innovation. I believe the best approach to accomplish this goal is harnessing the power of the free market to bring costs down and get treatments to patients faster.

Read the full op-ed here.

Biden at AACR: “What a difference a year makes”

Former U.S. Vice President Joe Biden speaks at a signing ceremony for the 21st Century Cures Act  

Former Vice President Joe Biden took the stage at the American Association for Cancer Research (AACR) annual meeting on Monday, with a speech titled ‘The Beau Biden Cancer Moonshot: Progress and Promise.

“What a difference a year makes,” he said in his opening remarks, streamed live by AACR.

Some 15 months after the Cancer Moonshot’s launch and one year after his first AACR keynote speech, there was a lot to report back to the Washington, D.C., crowd. What a difference a year makes, indeed.

There’s a movement.

Biden is not the leader of the cancer moonshot. He’s the inspiration.

“Look, I don’t have the answers,” he said. “But you all possess the potential to generate these answers.”

Trained as a lawyer, Biden educated himself about cancer after his son, Beau, was diagnosed with a brain tumor. He later passed away. That experience didn’t give him the expertise to navigate medicine’s way to a cure. It made him passionate about it, in a way that he can serve as a focal point for the necessary people to come together.

Silicon Valley showed up, politicians on both sides of the aisle, and Nobel laureates.

“I got a call from the chairman of the board of IBM,” Biden said. “Did I want Watson, the supercomputer, to partner with the department of defense and the VA?” 

With unprecedented data sharing and collaboration, the National Cancer Institutes launched the Genomic Data Commons to pool the information garnered through The Cancer Genome Atlas (TCGA), a database of 14,000 individuals’ genomic and health records. It has now expanded to 30,000 genomes.

Amazon called, Biden said, and agreed to open its cloud-computing platform for scientists using these massive databases. Since June, the data has been accessed 80 million times by researchers around the world.

Public support has been overwhelming. There is hope once again.

“You’ve lighted a fire under the public,” he said. “They’re beginning to believe again.”

There’s a cultural shift.

“For decades, we thought we could tackle cancer one discipline at a time,” Biden told the audience of cancer experts.

It’s not enough. Cancer uses every tool, system, and pathway at its disposal. The science community needs to meet each of those mechanisms head on, by uniting immunologists, virologists, geneticists, data scientists, chemical, biological and computer engineers and more. That’s happening, Biden said. The age of individual achievements in science is over.

Since its launch, the Cancer Moonshot has seeded at least 80 new collaborations. Many government-related projects have begun, he said, bringing together unlikely partnerships between the likes of NASA and the Department of Veterans Affairs.

There’s success in Washington.

In December, Congress passed the 21st Century Cures Act, which authorized an additional $6.3 billion in funding over seven years for health-related research, including $1.8 billion earmarked for cancer specifically.

Biden had the privilege to preside over the Cures Act, he said, which achieved remarkable bipartisan support.

With the passing of the Act, Republican Senator Mitch McConnell stood up to propose that the cancer initiative takes the name of Biden’s late son. The Beau Biden Cancer Moonshot.

“Those things don’t happen very much these days,” he recalled with a lot of emotion in his voice. “There is genuine, genuine bipartisan support.”

By this stage, the speech was starting to speak to something much more than the Cancer Moonshot. Late in the Obama administration, both sides had come together to pass something worthwhile.

“This is what [the American people] expect their government to do,” Biden said.

Oh, what a difference a year makes.

One year on, President Trump has taken the White House and is outlining major cuts to the NIH, the EPA — to the entire scientific field.

“The message sent out a few weeks ago in the President’s budget is counter to this hope and the progress we’ve made,” the 47th vice president of the United States told the audience.

He didn’t hold back.

“On the cusp of saving and extending lives for Americans, the President of the United States is not only not doubling-down on our investment, he’s proposing Draconian cuts.”

Funding would be set back 15 years, Biden said. By one estimate, new grant funding would be cut by 90 percent, given the multi-year commitments that the NIH has already made.

The ex-VP doesn’t believe the budget blueprint will pass Congress. However, the message it sends has already done a world of harm, communicating that science is not valued or worthy in the United States.

What a difference a year makes.

For Biden, the Cancer Moonshot was always about two things. It needed to inject urgency into the biomedical march towards a cure while also shifting the culture towards more collaboration, passion, and hope.

“You can not turn back the clock,” he said.

Not on his watch anyway.

Photo: MANDEL NGAN, AFP/Getty Images